THERAPY DOSSIER · th-3e5f7905cca4

Spinal cord-derived ependymal progenitor cells (epSPC) delivered in a tubular hyaluronic acid conduit containing poly(lactic acid) fibres (biohybrid scaffold)

Biologic · Spinal-cord ependymal progenitor cells in a hyaluronic-acid/PLA conduit; cell-biomaterial construct.

Evidence & regulatory context

Mechanism: Spinal-cord ependymal progenitor cells in a hyaluronic-acid/PLA conduit; cell-biomaterial construct.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30726582 ↗2019Reported benefit

Biohybrids for spinal cord injury repair.

RatSpinal cord injuryComplete transectionSprague-DawleyFemaleSurgical implantation of the cell-loaded conduit at the injury site

Model: Complete spinal cord transection

Biohybrid implantation delivered ependymal progenitor cells efficiently into the transected cord, increased preserved neuronal fibres with a horizontal directional pattern and enhanced GAP43 coexpression, reduced cavity and cyst formation and diminished astrocytic reactivity around the scar.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…